<DOC>
	<DOCNO>NCT00059358</DOCNO>
	<brief_summary>This study test amount anti-HIV drug blood cell HIV-infected patient also treat hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Zidovudine Levels HIV Infected Patients Being Treated HCV</brief_title>
	<detailed_description>An estimated 50,000 people Puerto Rico infect HCV . HIV HCV similar route transmission , HCV co-infection occur 8 % 23 % HIV infect patient . Researchers show treatment HCV Rebetron ( ribavirin plus interferon alfa-2b ) significantly decrease HCV viral load without affect HIV viral load . However , measurement intracellular level active form zidovudine ( ZDV-MP ZDV-TP ) perform . Such measurement need provide rational basis dose HIV/HCV co-infected patient . This study investigate intracellular exposure active ZDV metabolites prior treatment Rebetron treatment PEG-Intron ( pegylated interferon ) ribavirin . Participants study remain usual antiretroviral regimen ; change may make regimen first 4 week study . Upon study entry , participant intracellular pharmacokinetic study . During Week 2 , participant start either Rebetron PEG-Intron plus ribavirin therapy , intracellular pharmacokinetic study , undergo liver biopsy . Additional intracellular pharmacokinetic study perform Weeks 12 24 . Rebetron PEG-Intron plus ribavirin give 48 week . A second liver biopsy perform 24 week discontinue Rebetron PEG-Intron plus ribavirin therapy . Participants follow 72 week .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria HCVinfected HIV1 infection CD4 cell count &gt; 200 cells/mm³ within 30 day prior study entry HIV RNA &lt; 400 copies/ml within 90 day study entry Use zidovudine , lamivudine , PI and/or NNRTI ANC value &gt; = 1,500 ml³ within 30 day study entry Weight &gt; 50 kg ( 110 lb ) woman &gt; 60 kg ( 132 lb ) men Acceptable method contraception Ability willingness complete Baseline Adherence Questionnaire Documentation adherence confirm Baseline Adherence Questionnaire certify study official Exclusion Criteria Previous ribavirin therapy More 2 month interferon therapy Current use NRTI ZDV 3TC Hepatitis B surface antigen positive Infectious , autoimmune , tumoral , biliary , vascular liver disease Alcohol consumption 50 g/day Current use intravenous drug Hemoglobin level &lt; 10 gm/dl Methadone use Chemotherapy Certain medication Acute opportunistic bacterial infection require therapy time enrollment Hemoglobinopathy ( e.g. , thalassemia ) cause tendency hemolysis Psychiatric disorder , severe depression , history suicide attempt , suicidal ideation Renal disease require dialysis Significant coronary disease two risk factor coronary disease , &gt; 55 year old , hypertension , cholesterol &gt; 250 mg/dl Any clinically significant disease ( HIV HCV infection ) , opinion study official , would compromise outcome study Pregnancy Participation blind clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Interferon</keyword>
	<keyword>Co-infection</keyword>
	<keyword>Treatment experience</keyword>
</DOC>